Scarica l'app Stockscreener
15.95
1.73%
-0.28
Dopo l'orario di chiusura:
16.12
0.17
+1.07%
Precedente Chiudi:
$16.23
Aprire:
$16.21
Volume 24 ore:
119.29K
Relative Volume:
0.50
Capitalizzazione di mercato:
$531.26M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-12.56
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-3.45%
1M Prestazione:
-0.44%
6M Prestazione:
+77.62%
1 anno Prestazione:
+12.01%
Intervallo 1D:
$15.88
$16.52
Intervallo di 1 settimana:
$15.88
$17.44
Portata 52W:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.95 | 540.58M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright - Investing.com Nigeria
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock - Benzinga
Juniper Biomedical Appoints Frank Fischer To Board - citybiz
CORRECTING and REPLACING Juniper Biomedical Wins Neuromod Prize and Welcomes Frank Fischer to Board of Directors - Business Wire
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
NeuroPace sees Q4 revenue of about $26.6M - MSN
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue - Investing.com Australia
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue By Investing.com - Investing.com South Africa
US-based NeuroPace revenue expected to grow 24% in Q4 2025 - Medical Buyer
Profit Recap: Will NeuroPace Inc stock benefit from M AWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroPace reports 25% revenue growth for 2025, projects steady growth By Investing.com - Investing.com Nigeria
NeuroPace Reports Preliminary Q4, 2025 Revenue; Sets 2026 Guidance - marketscreener.com
NeuroPace (NASDAQ:NPCE) Shares Gap UpShould You Buy? - MarketBeat
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Investing News Network
NeuroPace, Inc. Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2026 - marketscreener.com
NeuroPace reports 25% revenue growth for 2025, projects steady growth - Investing.com
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.4% – What’s Next? - Defense World
Neurological Implants Market to Reach USD 12.39 Billion by 2031 | - openPR.com
Neuropace, Inc. (NPCE) Investor Outlook: Exploring the 13.5% Potential Upside in Medical Devices - DirectorsTalk Interviews
NeuroPace (NASDAQ:NPCE) Shares Down 4.4%Should You Sell? - MarketBeat
How resilient is NeuroPace Inc. stock in market downturnsDay Trade & Safe Investment Capital Preservation Plans - ulpravda.ru
When Will NeuroPace, Inc. (NASDAQ:NPCE) Turn A Profit? - 富途资讯
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Is NeuroPace Inc. stock oversold or undervaluedMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - Улправда
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
Can NeuroPace Inc. stock deliver sustainable ROE2026 world cup usa national team third place match playmakers high defensive line expert forecast breakdown - ulpravda.ru
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
User | bigspringherald.comNeuropace, Inc.Common Stock (Nasdaq:NPCE) Stock Quote - FinancialContent
UBS Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Neuropace, Inc. (NPCE) Stock Analysis: Uncovering an 18.90% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):